医学
多汗症
不利影响
肉毒毒素
皮肤病科
重症监护医学
脱敏(药物)
病因学
外科
内科学
受体
作者
Anna Campanati,Stamatios Gregoriou,Adamantia Milia-Argyti,George Kontochristopoulos,Giulia Radi,Federico Diotallevi,Emanuela Martina,Annamaria Offidani
标识
DOI:10.1080/14656566.2022.2083499
摘要
Idiopathic hyperhidrosis is a dysfunctional disorder involving eccrine sweat glands, and its impact on patients' daily quality of life is well known. Unlike some years ago, when only poor effective and safe therapeutic alternatives were available, nowadays, several emerging pharmacological active substances have gained significant space as treatment options.The authors report on, in this narrative review, the emerging data from the literature focusing on the pharmacological treatments to draw up a drug treatment flow chart for patients with idiopathic hyperhidrosis, taking into consideration specific differences among axillary, palmoplantar, and craniofacial hyperhidrosis.Idiopathic hyperhidrosis, regardless of the site of involvement, remains a functional disorder that places a significant burden on patients. After balancing efficacy against adverse events, systemic therapy, although off-label for all forms of hyperhidrosis, can be an added therapeutic option for patients with insufficient response to topical treatment. Until the pathophysiological mechanisms underlying hyperhidrosis are clear and the etiological therapeutic approach becomes realistic, the greatest challenge in the therapeutic management of hyperhidrotic patients seems to be the search for the most convenient combination between different therapeutic modalities (topical and systemic agents, and botulinum toxins) to achieve long-term control of the disease symptoms.
科研通智能强力驱动
Strongly Powered by AbleSci AI